entertainment -WSS

entertainment

author：comprehensive 2025-09-28 02:47:29 - browse：74

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead.

The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%.

In the study, 83% of patients with a condition called MASH and who were treated with survodutide saw significant improvements in their disease compared to 18% of those who received placebo. The study met its primary endpoint of improvements in MASH after 48 weeks without the worsening of fibrosis, a scarring of the liver, the companies said. Secondary endpoints were also met, including an improvement in fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Gene therapy denied for Afghan refugee whose father aided U.S.

explore

WSS

NIH documents show early flaws of $1.6 billion long Covid program

Ionis drug prevents swelling attacks due to hereditary angioedema

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

FDA early review: GLP

In shift, Texas to cover initial consult for Afghan baby's gene therapy

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

knowledge

entertainment

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Sports medicine is finally prioritizing gender equality

ASCO: AstraZeneca says CAR

Medical leaders decry Supreme Court decision on affirmative action

Merck to acquire Harpoon Therapeutics for $680 million

Alkermes shareholders re

At JPM 2024, hospital systems pitch financial strength to investors

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Wikipedia

Nonprofit, backed by Microsoft, to certify AI tools in health care

Shifting the focus from loneliness to social health

Kaiser's Risant Health gobbled up Geisinger. Who is next?

FDA early review: GLP

Nonprofit, backed by Microsoft, to certify AI tools in health care

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

explore

explore

focus

hotspot